Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies
ConclusionsOS has significantly improved nationally for patients newly diagnosed with clinical stage III melanoma in the era of novel melanoma therapies. OS outcomes will likely continue to evolve as these agents are increasingly utilized in the adjuvant setting. These data may help to better inform affected patients with respect to prognosis.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Melanoma | Skin Cancer | Statistics | Study